Please try another search
Prescient Therapeutics Ltd (AX:PTX) is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially conduct a pivotal study before out-licensing. It has resumed recruitment in the Phase Ib component of trials of lead anti-cancer compound PTX-200 in acute myeloid leukaemia (AML) and ovarian cancer, and is working with the FDA to recommence its Phase II breast cancer study. The company had A$6.9m cash on 30 September, sufficient to fund operations into FY19. We value Prescient at A$62m or A$0.29 per share.
PTX-100 to target RhoA-mutant lymphomas
Prescient has announced that it will resume clinical development of its second anti-cancer drug, PTX-100, in rare lymphomas where mutations of RhoA are common, such as angio-immunoblastic T-cell lymphoma. PTX-100 blocks an essential step in the activation of many downstream signalling proteins in the Ras oncogene signalling pathway, including RhoA. Clinical studies in this indication are expected to commence in mid-2018, after preclinical studies to confirm the mechanism of action of PTX-100 in RhoA mutant tumours are completed. The smaller trial sizes and potential for accelerated approval in this niche indication mean that Prescient could potentially conduct a pivotal study itself before seeking to out-license.
To read the entire report Please click on the pdf File Below:
Amid upcoming central bank meetings and crucial macroeconomic data releases, market sentiment is poised for potential shifts. While broader market indexes may continue to...
This year, the S&P 500 has seen a remarkable streak of 17 new all-time highs, outpacing many previous years. Notably, Warren Buffett's Berkshire Hathaway has stakes in two...
It had to end eventually. Whether last week’s shift in the pole position endures is something else entirely. But for the moment, US equities are no longer leading the horse race...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.